Loss of PTEN expression is associated with metastatic disease in patients with endometrial carcinoma
Loss of PTEN expression is associated with metastatic disease in patients with endometrial carcinoma
复制标题
DOI：
10.1002/cncr.10434
复制
发表时间：
2002-04-15
期刊：
影响因子：
6.2
通讯作者：
Akslen, LA
中科院分区：
文献类型：
--
作者：
Salvesen, HB;Stefansson, I;Akslen, LA
背景PTEN肿瘤抑制基因经常参与子宫内膜癌。据报道，杂合性丢失和突变是常见的，尽管这些变化的生物学重要性在很大程度上仍然未知。本研究的目的是通过免疫组织化学方法评估大量子宫内膜癌患者中PTEN的表达模式。我们研究了316例长期完整随访的子宫内膜癌患者的PTEN表达及其与临床病理变量、肿瘤标志物和生存率的相关性。PTEN蛋白表达主要在肿瘤细胞的胞浆中，在279例具有可评价结果的患者中有56例（20%）未见表达。在70个肿瘤（25%）中发现了异质性染色模式。PTEN表达缺失与转移性疾病之间存在显著相关性（P = 0.05）。然而，PTEN染色对存活率没有显著影响。子宫内膜癌中PTEN表达的缺失相对频繁，并且与转移性疾病显著相关。提示PTEN系统在某些子宫内膜癌中起重要作用，但还需进一步研究与各种基因改变相关的PTEN蛋白表达。(C)2002年美国癌症协会。
BACKGROUND. The PTEN tumor suppressor gene frequently is involved in endometrial carcinoma. Loss of heterozygosity and mutations reportedly are common, although the biologic importance of these changes remain largely unknown. The objective of this study was to assess the pattern of PTEN expression by immunohistochemistry in a large series of patients with endometrial carcinoma.METHODS. A population-based series of 316 patients with endometrial carcinoma who had long and complete follow-up was investigated for PTEN expression and its correlation with clinicopathologic variables, tumor markers, and survival.RESULTS. PTEN protein expression was mainly cytoplasmic in tumor cells, with no expression seen in 56 of 279 patients (20%) who had evaluable results. A heterogeneous staining pattern was found in 70 tumors (25%). A significant association between the loss of PTEN expression and metastatic disease was identified (P = 0.05). However, PTEN staining did not influence survival significantly.CONCLUSIONS. The loss of PTEN expression is relatively frequent in endometrial carcinoma and is associated significantly with metastatic disease. This indicates that the PTEN system plays an important role in some endometrial carcinomas, but further studies of PTEN protein expression related to various genetic alterations are necessary. (C) 2002 American Cancer Society.